Robert Wessman became the Executive Chairman of Alvogen in July 2009 and is now both the Chairman & CEO of the group. Wessman was CEO of Actavis Group, one of the largest generic pharmaceutical companies in the world for nine years.
A business graduate and former lecturer at the University of Iceland, Wessman began his career at the Icelandic shipping company Samskip where he quickly advanced to the post of CEO for Samskip in Germany. In 1999, he became President and CEO of Delta in 1999, which later formed Actavis through a merger with Pharmaco.
Wessman arrived at the helm of Actavis having built himself a solid reputation in Europe as a fast thinking and ambitious business man. From the start, he succeeded in turning his small Icelandic company into one of the leading global companies in the generic industry. In only seven years, the company grew from an annual turnover of EUR 57 million to more than EUR 1.6 billion, with a market capitalization of approximately EUR 3 billion.
Wessman is known for his clear focus and his ability to successfully combine operational efficiency and external growth through strategic acquisitions and the integration of over 30 companies. His achievements have made him the subject of a Harvard Business School Case Study published in May 2008, titled “Robert Wessman and the Actavis Winning Formula”.